IDH1 and glioblastoma: World Health Organization (WHO) proposes three molecular classifications for GBM, IDH wild-type (wt) (corresponding to primary GBM), IDH-mutant (corresponding to secondary GBM), and NOS (lacking any access to molecular diagnostic testing) (6).